| A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia RA Cantrell, M Sinkala, K Megazinni, S Lawson-Marriott, S Washington, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 49 (2), 190-195, 2008 | 283 | 2008 |
| Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia LB Mulenga, G Kruse, S Lakhi, RA Cantrell, SE Reid, I Zulu, EM Stringer, ... Aids 22 (14), 1821-1827, 2008 | 167 | 2008 |
| Detection of B. 1.351 SARS-CoV-2 variant strain—Zambia, december 2020 M Mwenda MMWR. Morbidity and mortality weekly report 70, 2021 | 164 | 2021 |
| Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey LB Mulenga, JZ Hines, S Fwoloshi, L Chirwa, M Siwingwa, S Yingst, ... The Lancet Global Health 9 (6), e773-e781, 2021 | 148 | 2021 |
| Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia BH Chi, RA Cantrell, I Zulu, LB Mulenga, JW Levy, BC Tambatamba, ... International journal of epidemiology 38 (3), 746-756, 2009 | 138 | 2009 |
| Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy JD Goldman, RA Cantrell, LB Mulenga, BC Tambatamba, SE Reid, ... AIDS research and human retroviruses 24 (8), 1031-1035, 2008 | 108 | 2008 |
| Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia DW Krebs, BH Chi, Y Mulenga, M Morris, RA Cantrell, L Mulenga, J Levy, ... AIDS care 20 (3), 311-317, 2008 | 100 | 2008 |
| Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within … NI Paton, C Kityo, J Thompson, I Nankya, L Bagenda, A Hoppe, J Hakim, ... The lancet HIV 4 (8), e341-e348, 2017 | 81 | 2017 |
| Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia L Mulenga, P Musonda, A Mwango, MJ Vinikoor, MA Davies, A Mweemba, ... Clinical infectious diseases 58 (10), 1473-1480, 2014 | 81 | 2014 |
| Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia BH Chi, A Mwango, M Giganti, LB Mulenga, B Tambatamba-Chapula, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 54 (1), 63-70, 2010 | 81 | 2010 |
| Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland F Schöni-Affolter, O Keiser, A Mwango, J Stringer, B Ledergerber, ... PloS one 6 (12), e27919, 2011 | 79 | 2011 |
| Status of HIV epidemic control among adolescent girls and young women aged 15–24 years—seven African countries, 2015–2017 K Brown MMWR. Morbidity and mortality weekly report 67, 2018 | 78 | 2018 |
| An empirical approach to defining loss to follow-up among patients enrolled in antiretroviral treatment programs BH Chi, RA Cantrell, A Mwango, AO Westfall, W Mutale, M Limbada, ... American journal of epidemiology 171 (8), 924-931, 2010 | 76 | 2010 |
| Retention and viral suppression in a cohort of HIV patients on antiretroviral therapy in Zambia: Regionally representative estimates using a multistage-sampling-based approach I Sikazwe, I Eshun-Wilson, K Sikombe, N Czaicki, P Somwe, A Mody, ... PLoS medicine 16 (5), e1002811, 2019 | 62 | 2019 |
| Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia E Marseille, MJ Giganti, A Mwango, A Chisembele-Taylor, L Mulenga, ... PloS one 7 (12), e51993, 2012 | 61 | 2012 |
| Age at antiretroviral therapy initiation predicts immune recovery, death, and loss to follow-up among HIV-infected adults in urban Zambia MJ Vinikoor, J Joseph, J Mwale, MA Marx, FM Goma, LB Mulenga, ... AIDS research and human retroviruses 30 (10), 949-955, 2014 | 58 | 2014 |
| First 100 persons with COVID-19—Zambia, March 18–April 28, 2020 PJ Chipimo MMWR. Morbidity and mortality weekly report 69, 2020 | 55 | 2020 |
| Impact of antiretroviral therapy on liver fibrosis among human immunodeficiency virus-infected adults with and without HBV coinfection in Zambia MJ Vinikoor, E Sinkala, R Chilengi, LB Mulenga, BH Chi, Z Zyambo, ... Clinical infectious diseases 64 (10), 1343-1349, 2017 | 52 | 2017 |
| Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up … JG Hakim, J Thompson, C Kityo, A Hoppe, A Kambugu, JJ van Oosterhout, ... The Lancet Infectious Diseases 18 (1), 47-57, 2018 | 51 | 2018 |
| Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia JR Koethe, MI Limbada, MJ Giganti, CK Nyirenda, L Mulenga, CW Wester, ... Aids 24 (13), 2117-2121, 2010 | 50 | 2010 |
